XLO News and Press, Xilio Therapeutics Inc. From 07/13/23

2023-07-13 17:25:28 ET Gainers: ACADIA Pharmaceuticals  ( ACAD ) +29% . Intuitive Machines ( LUNR ) +25% . Atara Biotherapeutics ( ATRA ) +5% . Xilio Therapeutics ( XLO ) +5% . Alector ( ALEC ) +3% . Losers: Theseus ...

Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer Favorable preliminary safety profile for XTX101 observed at the recommended Phase 2 dose of 150 mg once every six weeks WALTHAM, Mass., May 25, 2023 (GLOBE NEW...

2023-05-09 08:54:44 ET Xilio Therapeutics press release ( NASDAQ: XLO ): Q1 GAAP EPS of -$0.83 beats by $0.06 . Cash and cash equivalents were $93.3 million as of March 31, 2023, compared to $120.4 million as of December 31, 2022. For further details see: ...

Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK, PD, and anti-tumor activity data for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in the second quarter of 2023 Ended first quarter of 2023 with $93.3 ...

2023-04-11 09:30:29 ET Innovative Eyewear ( LUCY ) +129% on launching the first ChatGPT enabled smart eyewear. ZeroFox Holdings ( ZFOX ) +63% on partnering with Google Cloud to disrupt phishing attacks and malicious URLs.WW International WW +38% as Sequence deal closes, Goldman move...

WALTHAM, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the Compensation Committee of the Board of Directors granted a non-quali...

Xilio Therapeutics press release ( NASDAQ: XLO ): Q4 GAAP EPS of -$0.82 misses by $0.08 . Ended 2022 with $120.4 million in cash and cash equivalents; continue to anticipate cash runway into the second quarter of 2024 For further details see: Xilio Therapeutics GAAP ...

Initial clinical data from XTX101, XTX202 and XTX301 clinical trials anticipated in 2023 XTX202, a tumor-activated IL-2, demonstrated preliminary clinical pharmacodynamic evidence of tumor-selective activation, providing initial clinical platform validation Anticipate initiating...

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced its participation in the following upcoming investor conferences: Cowen 43 ...

WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in Citi&#...